Teva Goes Schizophrenic

Teva Pharmaceutical Industries have announced that a U.S. court has granted 180 days of exclusivity for selling a generic version of Risperdal – a widely used schizophrenia drug patented by Johnson & Johnson. The drug, which is also used to treat bipolar mania, had U.S. sales of about $2.5 billion in 2007.

The first generic to challenge a patented drug gets an exclusivity period for 6 months. Once the exclusivity period finishes, other generic manufacturers generally compete and prices plummet.

Categories: Intellectual Property, Israel IP, Israel Related, News, Patents, pharmaceuticals, pharmaceuticals and Biotechnology, Teva, US

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: